NASDAQ:DRUG Bright Minds Biosciences Q2 2026 Earnings Report $77.60 -0.40 (-0.51%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Bright Minds Biosciences EPS ResultsActual EPS-$0.80Consensus EPS -$0.86Beat/MissBeat by +$0.06One Year Ago EPSN/ABright Minds Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABright Minds Biosciences Announcement DetailsQuarterQ2 2026Date5/20/2026TimeBefore Market OpensConference Call DateTuesday, May 19, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Bright Minds Biosciences Earnings HeadlinesBright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal TrialsAugust 10, 2026 | seekingalpha.comBright Minds Biosciences (DRUG) Projected to Release Quarterly Earnings on ThursdayAugust 6, 2026 | americanbankingnews.comElon's next move will be bigger than the IPO – and it could happen any day nowHedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning streak - says the SpaceX IPO wasn't the main event. It was the trigger. He's identified what he calls the 'Final Phase of Elon's Master Plan,' and one specific ticker he believes could see billions forced into it within days. It's not SpaceX, Tesla, or any company you'd associate with Elon Musk. Larry is revealing the ticker free today.August 14 at 1:00 AM | Brownstone Research (Ad)Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives $143.83 Consensus Target Price from AnalystsAugust 5, 2026 | americanbankingnews.comVistagen Appoints Douglas J. Williamson to its Board of DirectorsJuly 31, 2026 | globenewswire.comBright Minds Biosciences to Present at Jefferies Global Healthcare ConferenceMay 26, 2026 | globenewswire.comSee More Bright Minds Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email. Email Address About Bright Minds BiosciencesBright Minds Biosciences (NASDAQ:DRUG), trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments. The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders. Its second program, BMB-103, is in preclinical development targeting neuroinflammation and neuronal survival pathways relevant to Alzheimer’s disease. Bright Minds Biosciences operates research facilities in Vancouver and Montreal, collaborating with academic institutions and industry partners to advance its pipeline through both early-stage and later-stage clinical studies. Founded in 2020, Bright Minds completed its initial public listing to support ongoing research and development activities. The company’s leadership team includes experienced researchers, medicinal chemists and clinical development experts committed to translating cutting-edge neuroscience into scalable therapies. By focusing on small-molecule alternatives to traditional biologics, Bright Minds Biosciences seeks to offer patients oral treatments with favorable safety profiles and broad commercial applicability. View Bright Minds Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
